JP2006513220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006513220A5 JP2006513220A5 JP2004563916A JP2004563916A JP2006513220A5 JP 2006513220 A5 JP2006513220 A5 JP 2006513220A5 JP 2004563916 A JP2004563916 A JP 2004563916A JP 2004563916 A JP2004563916 A JP 2004563916A JP 2006513220 A5 JP2006513220 A5 JP 2006513220A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- linear
- pharmaceutical composition
- compound
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 41
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 229910052739 hydrogen Inorganic materials 0.000 claims 27
- 201000010099 disease Diseases 0.000 claims 23
- 125000001475 halogen functional group Chemical group 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000002431 hydrogen Chemical class 0.000 claims 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 230000001404 mediated effect Effects 0.000 claims 8
- -1 trifluorophenoxy Chemical group 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- 230000006907 apoptotic process Effects 0.000 claims 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 210000000056 organ Anatomy 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 208000020084 Bone disease Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 208000034578 Multiple myelomas Diseases 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 208000006011 Stroke Diseases 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 201000006474 Brain Ischemia Diseases 0.000 claims 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 4
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 4
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 4
- 208000023105 Huntington disease Diseases 0.000 claims 4
- 208000028389 Nerve injury Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 206010040070 Septic Shock Diseases 0.000 claims 4
- 206010008118 cerebral infarction Diseases 0.000 claims 4
- 210000004351 coronary vessel Anatomy 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 208000031225 myocardial ischemia Diseases 0.000 claims 4
- 230000008764 nerve damage Effects 0.000 claims 4
- 230000036303 septic shock Effects 0.000 claims 4
- 208000020431 spinal cord injury Diseases 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 206010033645 Pancreatitis Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 231100000360 alopecia Toxicity 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 230000030833 cell death Effects 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 230000001066 destructive effect Effects 0.000 claims 3
- 235000005911 diet Nutrition 0.000 claims 3
- 230000000378 dietary effect Effects 0.000 claims 3
- 208000001848 dysentery Diseases 0.000 claims 3
- 208000019622 heart disease Diseases 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 231100000283 hepatitis Toxicity 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 208000021039 metastatic melanoma Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 206010034674 peritonitis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 3
- 206010043554 thrombocytopenia Diseases 0.000 claims 3
- 230000009529 traumatic brain injury Effects 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 206010019773 Hepatitis G Diseases 0.000 claims 2
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 claims 2
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102100039898 Interleukin-18 Human genes 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000027747 Kennedy disease Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000024777 Prion disease Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000005000 autoimmune gastritis Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000000718 duodenal ulcer Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 210000004165 myocardium Anatomy 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004360 trifluorophenyl group Chemical group 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 102000011727 Caspases Human genes 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 1
- 208000012895 Gastric disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000005807 Japanese encephalitis Diseases 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000919 anti-host Effects 0.000 claims 1
- 239000010836 blood and blood product Substances 0.000 claims 1
- 229940125691 blood product Drugs 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004720 cerebrum Anatomy 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 0 *CC(C(CC(*)=O)NC(C(*)N(C=Cc1cc(*)c(*)cc11)C1=O)=O)=O Chemical compound *CC(C(CC(*)=O)NC(C(*)N(C=Cc1cc(*)c(*)cc11)C1=O)=O)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43513302P | 2002-12-20 | 2002-12-20 | |
| PCT/US2003/040870 WO2004058718A1 (en) | 2002-12-20 | 2003-12-22 | 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006343613A Division JP2007070368A (ja) | 2002-12-20 | 2006-12-20 | ４−オキソ−３−（１−オキソ−１ｈ−イソキノリン−２−イルアセチルアミノ）−ペンタン酸のエステル誘導体およびアミド誘導体、ならびにカスパーゼインヒビターとしてのそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006513220A JP2006513220A (ja) | 2006-04-20 |
| JP2006513220A5 true JP2006513220A5 (https=) | 2007-02-15 |
| JP4675628B2 JP4675628B2 (ja) | 2011-04-27 |
Family
ID=32682166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563916A Expired - Fee Related JP4675628B2 (ja) | 2002-12-20 | 2003-12-22 | ４−オキソ−３−（１−オキソ−１ｈ−イソキノリン−２−イルアセチルアミノ）−ペンタン酸のエステル誘導体およびアミド誘導体、ならびにカスパーゼインヒビターとしてのそれらの使用 |
| JP2006343613A Pending JP2007070368A (ja) | 2002-12-20 | 2006-12-20 | ４−オキソ−３−（１−オキソ−１ｈ−イソキノリン−２−イルアセチルアミノ）−ペンタン酸のエステル誘導体およびアミド誘導体、ならびにカスパーゼインヒビターとしてのそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006343613A Pending JP2007070368A (ja) | 2002-12-20 | 2006-12-20 | ４−オキソ−３−（１−オキソ−１ｈ−イソキノリン−２−イルアセチルアミノ）−ペンタン酸のエステル誘導体およびアミド誘導体、ならびにカスパーゼインヒビターとしてのそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7612091B2 (https=) |
| EP (1) | EP1581501A1 (https=) |
| JP (2) | JP4675628B2 (https=) |
| CN (1) | CN100366612C (https=) |
| AU (1) | AU2003303345A1 (https=) |
| CA (1) | CA2511235A1 (https=) |
| TW (1) | TW200500343A (https=) |
| WO (1) | WO2004058718A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| PE20040728A1 (es) | 2002-06-28 | 2004-10-23 | Vertex Pharma | Inhibidores de caspasa |
| TW200500343A (en) * | 2002-12-20 | 2005-01-01 | Vertex Pharma | Caspase inhibitors and uses thereof |
| PE20050159A1 (es) * | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| SG150547A1 (en) * | 2004-03-12 | 2009-03-30 | Vertex Pharma | Processes and intermediates |
| MXPA06013256A (es) * | 2004-05-15 | 2007-02-08 | Vertex Pharma | Tratamiento de crisis convulsivas utilizando inhibidores ice. |
| CA2567080A1 (en) | 2004-05-27 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Ice inhibitors for the treatment of autoinflammatory diseases |
| ES2614113T3 (es) * | 2004-09-17 | 2017-05-29 | Biomas Ltd. | Uso de tricloro (dioxietilen-O,O) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta |
| ATE543803T1 (de) * | 2004-11-24 | 2012-02-15 | Vertex Pharma | 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren |
| FR2923160B1 (fr) | 2007-11-02 | 2013-07-26 | Pasteur Institut | Composes destines a prevenir ou traiter une infection virale. |
| US9116157B2 (en) | 2010-11-05 | 2015-08-25 | Brandeis University | Ice-cleaved alpha-synuclein as a biomarker |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
| ES2751652T3 (es) | 2014-05-12 | 2020-04-01 | Conatus Pharmaceuticals Inc | Tratamiento con inhibidor de caspasa emricasan de las complicaciones por las enfermedades hepáticas crónicas |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| JP2019500397A (ja) | 2015-12-31 | 2019-01-10 | クオナトウス ファーマシューティカルズ，インコーポレイテッド | カスパーゼ阻害剤を肝疾患の治療に使用する方法 |
| CN107286091B (zh) * | 2016-04-11 | 2020-06-19 | 中国海洋大学 | 一种胺基Sclerotiorin衍生物在制备抗结核药物中的应用 |
| RU2019113150A (ru) | 2016-10-05 | 2020-11-06 | Новартис Аг | Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения |
| US11447497B2 (en) | 2018-06-29 | 2022-09-20 | Histogen, Inc. | (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases |
| WO2020222541A1 (ko) * | 2019-04-30 | 2020-11-05 | 주식회사 엘지화학 | 캐스파제 저해제의 프로드럭 |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| DD232699A1 (de) | 1983-11-18 | 1986-02-05 | Adw Ddr | Verfahren zur herstellung von chinazolin-4-on-3-alkansaeuren und deren estern |
| FR2582514B1 (fr) * | 1985-05-30 | 1988-02-19 | Rhone Poulenc Sante | Medicaments a base d'amides, nouveaux amides et leur preparation |
| US5714484A (en) | 1993-12-08 | 1998-02-03 | Prototek, Inc. | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) * | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6420522B1 (en) * | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5565430A (en) | 1994-08-02 | 1996-10-15 | Sterling Winthrop Inc. | Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors |
| EP0761680A3 (en) | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
| WO1998016502A1 (en) | 1996-10-11 | 1998-04-23 | Warner-Lambert Company | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
| US6063794A (en) * | 1996-10-11 | 2000-05-16 | Cor Therapeutics Inc. | Selective factor Xa inhibitors |
| NZ334906A (en) | 1996-10-11 | 2000-09-29 | Basf Ag | A sulphonamido pentanoic acid derivative useful as an interleukin-1-beta converting enzyme inhibitor |
| WO1998018781A2 (en) | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| BR0010349B1 (pt) | 1999-05-07 | 2011-10-04 | derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores. | |
| DK1176956T3 (da) | 1999-05-07 | 2008-05-26 | Encysive Pharmaceuticals Inc | Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer |
| AR026748A1 (es) * | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
| KR100322546B1 (ko) | 2000-05-08 | 2002-03-18 | 윤종용 | 독립적인 전원 전압을 사용하는 메모리와 메모리 컨트롤러간의 인터페이스 시스템 |
| EP1289993B9 (en) * | 2000-06-07 | 2008-08-20 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| WO2002022611A2 (en) * | 2000-09-13 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| JP4428926B2 (ja) * | 2001-05-23 | 2010-03-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | カスパーゼインヒビターおよびそれらの使用 |
| AU2002348533A1 (en) | 2001-10-09 | 2003-05-26 | Vertex Pharmaceuticals Incorporated | Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof |
| US7410956B2 (en) * | 2002-02-11 | 2008-08-12 | Vertex Pharmaceuticals Incorporated | Caspase inhibitor prodrugs |
| US7960398B2 (en) | 2002-04-19 | 2011-06-14 | Vertex Pharmaceuticals Incorporated | Regulation of TNF-alpha |
| PE20040728A1 (es) * | 2002-06-28 | 2004-10-23 | Vertex Pharma | Inhibidores de caspasa |
| TW200500343A (en) | 2002-12-20 | 2005-01-01 | Vertex Pharma | Caspase inhibitors and uses thereof |
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| FI117148B (fi) | 2004-07-09 | 2006-06-30 | Kone Corp | Menetelmä ja laitteisto aksiaalivuo-kestomagneettitahtikoneen kokoonpanoa varten |
| US7296449B2 (en) * | 2004-09-21 | 2007-11-20 | Ball Corporation | Dry hydraulic can shaping |
| ATE543803T1 (de) | 2004-11-24 | 2012-02-15 | Vertex Pharma | 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren |
| JP2007040368A (ja) * | 2005-08-02 | 2007-02-15 | Ntn Corp | プーリの固定構造 |
-
2003
- 2003-12-22 TW TW092136402A patent/TW200500343A/zh unknown
- 2003-12-22 CA CA002511235A patent/CA2511235A1/en not_active Abandoned
- 2003-12-22 AU AU2003303345A patent/AU2003303345A1/en not_active Abandoned
- 2003-12-22 EP EP03814289A patent/EP1581501A1/en not_active Withdrawn
- 2003-12-22 JP JP2004563916A patent/JP4675628B2/ja not_active Expired - Fee Related
- 2003-12-22 CN CNB2003801092852A patent/CN100366612C/zh not_active Expired - Fee Related
- 2003-12-22 WO PCT/US2003/040870 patent/WO2004058718A1/en not_active Ceased
- 2003-12-22 US US10/743,563 patent/US7612091B2/en not_active Expired - Fee Related
-
2006
- 2006-12-20 JP JP2006343613A patent/JP2007070368A/ja active Pending
-
2009
- 2009-09-18 US US12/562,277 patent/US8071618B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006513220A5 (https=) | ||
| JP2005533825A5 (https=) | ||
| JP2003535865A5 (https=) | ||
| RU2005102094A (ru) | Ингибиторы каспазы и их применение | |
| JP2003534325A5 (https=) | ||
| TWI726030B (zh) | 一種ｂｔｋ激酶抑制劑的結晶形式及其製備方法 | |
| JP2023508772A (ja) | Ｊａｋ阻害剤化合物及びその使用 | |
| CA2401832A1 (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
| RU2005140657A (ru) | Ингибиторы каспаз и их применение | |
| JP2003506389A5 (https=) | ||
| JP2004509120A5 (https=) | ||
| UA81808C2 (en) | Normal;heading 1;heading 2;DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PROCESS FOR PREPARATION AND THERAPEUTIC USES THEREOF | |
| CA2422708A1 (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
| JP2011517443A5 (https=) | ||
| WO2004113352A1 (en) | Silylated heterocyclylurea derivatives as cytokine-inhibitors | |
| JP2009502922A5 (https=) | ||
| JP2007525503A5 (https=) | ||
| KR20200011388A (ko) | Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이를 포함하는 약학적 조성물 | |
| AU2023369987A1 (en) | Process for the preparation of a gadolinium contrast agent | |
| RU2006134258A (ru) | Ингибиторы каспаз и их применение | |
| CN101939289A (zh) | 用于制备伏立诺他的新方法 | |
| JP5460614B2 (ja) | アゼチジン誘導体、それらの調製、およびそれらの治療における適用 | |
| JPH03193799A (ja) | ３―（ｌ―ピログルタミル）―ｌ―チアゾリジン―４―カルボン酸およびその誘導体の製造方法 | |
| WO2015097850A1 (ja) | ２－アミノニコチン酸ベンジルエステル誘導体の製造方法 | |
| FR2874012A1 (fr) | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |